One adult developed fatal bone marrow depression (medullary aplasia) after several days of dosing that was at least 10-fold greater than recommended for the patientβ†β†s estimated degree of renal impairment.

It is expected that an overdose of Valcyte tablets could also possibly result in increased renal toxicity (see PRECAUTIONS: General and DOSAGE AND ADMINISTRATION: Renal Impairment ).

Since ganciclovir is dialyzable, dialysis may be useful in reducing serum concentrations in patients who have received an overdose of Valcyte tablets (see CLINICAL PHARMACOLOGY: Special Populations: Hemodialysis ). Adequate hydration should be maintained. The use of hematopoietic growth factors should be considered (see CLINICAL PHARMACOLOGY: Special Populations : Hemodialysis).

Reports of overdoses with intravenous ganciclovir have been received from clinical trials and during postmarketing experience. The majority of patients experienced one or more of the following adverse events:

Hematological toxicity: pancytopenia, bone marrow depression, medullary aplasia, leukopenia, neutropenia, granulocytopenia

Hepatotoxicity: hepatitis, liver function disorder

Renal toxicity: worsening of hematuria in a patient with pre-existing renal impairment, acute renal failure, elevated creatinine

Gastrointestinal toxicity: abdominal pain, diarrhea, vomiting

Neurotoxicity: generalized tremor, convulsion

Valcyte tablets are contraindicated in patients with hypersensitivity to valganciclovir or ganciclovir.

Bookmark this page: